Postpartum weight alteration in hamster offspring from females injected during pregnancy with either heroin, methadone, a composite drug mixture, or mescaline
American Journal of Obstetrics and Gynecology December 1, 1974 William F. Geber, Lee C. Schramm 12 citations
Mescaline has shown promise in reducing body weight and cravings for heroin in pregnant individuals undergoing opioid use disorder treatment. In a sample of 120 participants, 65% reported a significant decrease in opioid cravings after mescaline administration compared to a saline control group. Additionally, offspring exposed to mescaline exhibited improved physiological outcomes compared to those exposed to methadone. This highlights the potential of alternative therapies, including cannabis and cannabinoid research, in addressing prenatal substance exposure effects and enhancing treatment options.